Galera Therapeutics (GRTX)
OTHER OTC:GRTX
GRTX Stock Chart & Stats
$0.02
<$0.01(0.99%)
At close: 4:00 PM EST
$0.02
<$0.01(0.99%)
Day’s Range― - ―
52-Week Range$0.02 - $0.06
Previous CloseN/A
Volume48.38K
Average Volume (3M)63.57K
Market Cap
$3.14M
Enterprise Value-$3.21M
Total Cash (Recent Filing)$6.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)<0.1
Beta0.69
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding75,462,390
10 Day Avg. Volume87,114
30 Day Avg. Volume63,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.36
Enterprise Value/Market Cap-1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deleveraging / Balance-sheet RepairElimination of debt and a shift to modest positive equity in 2025 materially reduces near-term solvency risk. This repair provides a firmer capital cushion and more strategic optionality for hiring, trial funding, or partnering over the next several quarters, improving survivability.
Capital-structure FlexibilityThe preferred-stock conversion amendment gives management discretion to simplify the capital structure and execute financings or strategic transactions quickly. That governance tool reduces potential stakeholder deadlocks and supports adaptive capital planning over medium term.
Management Continuity For ReportingProviding retention incentives to the chief accounting officer boosts continuity and reduces execution risk around financial reporting and compliance. Stable financial leadership enhances credibility with investors and counterparties during refinancing or partnership negotiations.
Bears Say
No Revenue / Pre-revenue StatusA multi-year absence of revenue leaves the company dependent on external capital rather than operating cash flows. Without validated commercial products or recurring sales, funding needs remain structural and raise long-term dilution and sustainability concerns for development programs.
Persistent Negative Cash GenerationSustained negative operating and free cash flow indicates ongoing burn from R&D without internal funding replacement. The 2025 $0 cash flow does not prove durable self-funding, meaning the firm will likely need further financing, constraining strategic choices and extending dilution risk.
Earnings Quality ConcernsA reported net income swing unaccompanied by positive EBIT suggests one-off or accounting-driven gains, not improved core profitability. This undermines confidence in sustainable earnings power and signals that operating losses continue beneath the headline result.
Galera Therapeutics News
GRTX FAQ
What was Galera Therapeutics’s price range in the past 12 months?
Galera Therapeutics lowest stock price was $0.01 and its highest was $0.06 in the past 12 months.
What is Galera Therapeutics’s market cap?
Galera Therapeutics’s market cap is $3.14M.
When is Galera Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Galera Therapeutics’s earnings last quarter?
Currently, no data Available
Is Galera Therapeutics overvalued?
According to Wall Street analysts Galera Therapeutics’s price is currently Overvalued.
Does Galera Therapeutics pay dividends?
Galera Therapeutics does not currently pay dividends.
What is Galera Therapeutics’s EPS estimate?
Galera Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galera Therapeutics have?
Galera Therapeutics has 75,462,390 shares outstanding.
What happened to Galera Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Galera Therapeutics?
Currently, no hedge funds are holding shares in GRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galera Therapeutics
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Technical Analysis
Ownership Overview
0.26% Insiders
<0.01% Mutual Funds
3.90% Other Institutional Investors
95.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---